AACR Poster Presentation: “KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors

by s2desi5_ksqtherapeutics | Jun 22, 2020 | Uncategorized

Click to download PDF file.

KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

by s2desi5_ksqtherapeutics | Sep 24, 2020 | Uncategorized

CAMBRIDGE, Mass., Sept. 24, 2020– KSQ® Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present...

KSQ® Therapeutics Presents First Preclinical Data for KSQ-4279, a Novel USP1 Inhibitor, for the Treatment of BRCA-Deficient Cancers

by s2desi5_ksqtherapeutics | Oct 24, 2020 | Uncategorized

2020 ENA Plenary Slide Deck: “USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors” 2020 ENA Poster: “Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers” Data...

KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies

by s2desi5_ksqtherapeutics | Jan 13, 2021 | Uncategorized

Collaboration includes two T-cell programs and an expansive discovery program to identify natural killer (NK) cell targets Potential for more than $100M in upfront and preclinical milestone payments, and eligible to receive additional development and commercialization...

KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer

by s2desi5_ksqtherapeutics | Jan 25, 2021 | Uncategorized

Dr. Rizvi brings a Proven Track Record and Commitment to Innovation, Collaboration & Team Building CAMBRIDGE, Mass., January 25, 2021 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the...